Five things to know:
- The Drug Enforcement Administration and the Department of Health and Human Services issued a final rule on Nov. 15 extending telemedicine prescribing flexibilities for an additional year, according to a news release from the American Hospital Association.
- Under the extension, the agencies will waive the in-person visit requirement for prescribing controlled substances virtually, pushing the deadline to Dec. 31, 2025.
- This includes stimulant medications for attention-deficit/hyperactivity disorder, anxiety medications, and medications for opioid use disorder, among others.
- Prior to the COVID-19 pandemic, patients needed at least one in-person visit to receive controlled substances.
- The announcement comes after the American Hospital Association advocated for the agencies to extend the prescribing flexibility, which was set to expire at the end of 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.